Medincell's partner teva provides guidance for uzedy in 2024 and an update on the treatment-candidate of olanzapine long-acting injectable (lai)

Montpellier, france--(business wire)--medincell (paris:medcl): access here the complete press release about uzedy during the q4 2023 earnings call held today by teva pharmaceutical industries ltd., president and ceo richard francis stated that he expects a strong uptake and significant growth for uzedy in 2024. he notably provided the annual revenue guidance for uzedy, projecting approximately $80 million for 2024. this revenue projection is aligned with medincell's forecasted earnings from uze.
TEVA Ratings Summary
TEVA Quant Ranking